CALC

CalciMedicaF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.10

Analysis reference price unavailable

Analysis 2026-08-28 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$0.45

Analysis reference price unavailable

Analysis 2026-08-28 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$0.18

Analysis reference price unavailable

Analysis 2026-08-28 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-28

AI commentary

Sentiment is fragile and monitoring-driven. Recent news coverage is sparse, social coverage is unavailable, and analyst revision data are not provided. Stored earnings coverage described a 6.22% pre-market gain despite the Q2 loss miss, suggesting investors focused on financing and the clinical roadmap rather than current earnings [#PR-EARNINGS-2026-08-11]. The low-coverage, micro-cap setting warrants caution and limits confidence in the price scenarios.

RankAlpha Sentiment Codex - 2026-08-28

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-11-26eventPulmonary hypertension clinical and regulatory milestonesHigh impact

Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension and a CM5480 IND submission are both anticipated in mid-2027. These are the clearest defined upside milestones in the current company roadmap [#SEC-8K-2026-08-11].

2026-11-26catalystFinancing and dilution remain central risksHigh impact

The company reported a private placement of up to approximately $49 million, including about $15 million of upfront proceeds, to advance its pulmonary hypertension strategy. Financing improves optionality but leaves capital-structure and execution risk material for a micro-cap biotech [#PR-EARNINGS-2026-08-11].

2026-11-26catalystQ2 earnings miss limits near-term supportHigh impact

Stored earnings coverage reported a second-quarter loss of $0.45 per share versus a $0.26 analyst estimate, while net loss widened year over year. The reported positive initial price reaction appeared to prioritize the clinical roadmap and financing over the earnings miss [#PR-EARNINGS-2026-08-11].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-28 • Updated nightlySource: Internal modelMethodology